Atherosclerosis: Sartans+Statins
We want to test the effects of Sartans+Statins combinations in small therapeutic doses on the condition of vessel. Positive results will indicate a reduced risk of CVD in the near future and postponed pathologies development, which will become a direct opportunity to increase individual life expectancy.

A recently published article on biomarkers of aging has confirmed the right choice of indicators to measure. Researchers have shown that IL-6, C-reactive protein and cystatin C, which we have also chosen, grow with age. Adding intima-media thickness (IMT) to this list, we get the optimal biomarkers panel for this research.
Other trials
Clinical trials we plan to conduct at the expense of funds collected via ICO.